Scarica l'app Stockscreener
1.60
1.27%
0.02
Dopo l'orario di chiusura:
1.56
-0.04
-2.50%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRTX Giù?
Forum
Previsione
Frazionamento azionario
Heron Therapeutics Inc Borsa (HRTX) Ultime notizie
California public company relocates to North Carolina - The Business Journals
Heron Therapeutics Relocates Headquarters to North Carolina - TipRanks
Heron Therapeutics, Inc. Announces Corporate Headquarters Relocation to Cary, North Carolina - Marketscreener.com
Heron Therapeutics (NASDAQ:HRTX) Rating Lowered to “Hold” at StockNews.com - Defense World
Heron Therapeutics (NASDAQ:HRTX) Cut to "Hold" at StockNews.com - MarketBeat
Fmr LLC Has $859,000 Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Verition Fund Management LLC - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stake Lowered by Charles Schwab Investment Management Inc. - Defense World
U.S. District Court Upholds Validity of CINVANTI® Patents - The Eastern Progress Online
Exploring Three High Growth Tech Stocks In The United States - Yahoo Finance
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer - The Eastern Progress Online
StockNews.com Upgrades Heron Therapeutics (NASDAQ:HRTX) to "Buy" - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Rating Increased to Buy at StockNews.com - Defense World
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance - Kilgore News Herald
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors - The Eastern Progress Online
StockNews.com Downgrades Heron Therapeutics (NASDAQ:HRTX) to Hold - Defense World
Relief For Heron Therapeutics After The Court Win On Cinvanti - Seeking Alpha
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Heron Therapeutics wins patent case for CINVANTI drug - Investing.com
Heron Therapeutics wins patent case for CINVANTI drug By Investing.com - Investing.com Canada
Heron Therapeutics Shares Soar 91% on Patent Dispute Win - MarketWatch
Heron Therapeutics Wins Major Patent Battle Over CINVANTI, Blocks Generic Until 2035 - StockTitan
Heron Therapeutics: Approved Therapy With Blockbuster Potential But Meager Revenues (NASDAQ:HRTX) - Seeking Alpha
Biotech Finds Mid-Week Success Following Q4 Earnings Release - MSN
Principal Financial Group Inc. Has $204,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics: Q3 Earnings Snapshot - Marketscreener.com
Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to “Hold” - Defense World
Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to "Hold" - MarketBeat
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Heron Therapeutics Q3 2024 Earnings Preview - MSN
Heron Therapeutics Inc (NASDAQ: HRTX) Declines -1.68%: This $177.95 million Stock Could Go Down -669.23% - Stocks Register
Short Interest in Heron Therapeutics, Inc. (NASDAQ:HRTX) Declines By 6.0% - MarketBeat
Northland Capmk Has Pessimistic View of HRTX Q4 Earnings - Defense World
Equities Analysts Set Expectations for HRTX Q4 Earnings - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Raised to Buy at StockNews.com - Defense World
Heron Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Needham & Company LLC Has Lowered Expectations for Heron Therapeutics (NASDAQ:HRTX) Stock Price - MarketBeat
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge - Simply Wall St
Heron Therapeutics Inc (HRTX) Quarterly 10-Q Report - Quartz
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30% - Simply Wall St
Earnings call: Heron Therapeutics projects higher Q4 revenue By Investing.com - Investing.com UK
Starbucks To $77? Here Are 10 Top Analyst Forecasts For WednesdayStarbucks (NASDAQ:SBUX) - Benzinga
Heron Therapeutics Reports Q3 2024 Results and Narrows Guidance - TipRanks
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
U.S. Stock market most volatile stocks: Neuronetics(-47.27%), Heron Therapeutics(-20.15%) and LogicMark(+94.36%) in early trading - Business Upturn
Heron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Heron Therapeutics reports Q3 EPS (3c), consensus (3c) - TipRanks
Heron Therapeutics (HRTX) Set to Announce Earnings on Tuesday - Defense World
0.50%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):